A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naive Mantle Cell Lymphoma (BRUIN MCL-321)

Grants and Contracts Details

StatusActive
Effective start/end date9/29/216/28/24

Funding

  • IQVIA RDS Incorporated: $128,759.00